EP4178538A1 - Zweikomponenten-reaktionshydrogel für multifunktionswundverband und verfahren zu seiner herstellung - Google Patents
Zweikomponenten-reaktionshydrogel für multifunktionswundverband und verfahren zu seiner herstellungInfo
- Publication number
- EP4178538A1 EP4178538A1 EP21763000.3A EP21763000A EP4178538A1 EP 4178538 A1 EP4178538 A1 EP 4178538A1 EP 21763000 A EP21763000 A EP 21763000A EP 4178538 A1 EP4178538 A1 EP 4178538A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrogel
- component
- components
- hyaluronic acid
- reactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 10
- 229920001661 Chitosan Polymers 0.000 claims abstract description 43
- 206010052428 Wound Diseases 0.000 claims abstract description 30
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 30
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 28
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 28
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 28
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 16
- 230000001684 chronic effect Effects 0.000 claims abstract description 15
- 230000001172 regenerating effect Effects 0.000 claims abstract description 11
- 238000012377 drug delivery Methods 0.000 claims abstract description 9
- 244000052769 pathogen Species 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 6
- 230000035876 healing Effects 0.000 claims abstract description 6
- 238000011065 in-situ storage Methods 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 229940045110 chitosan Drugs 0.000 claims description 42
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 229960001225 rifampicin Drugs 0.000 claims description 14
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 238000001879 gelation Methods 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000002211 L-ascorbic acid Substances 0.000 claims description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- FLASNYPZGWUPSU-SICDJOISSA-N chitosan Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H](O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](N)[C@H]2O)CO)[C@H](N)[C@H]1O)CO)NC(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N FLASNYPZGWUPSU-SICDJOISSA-N 0.000 claims description 7
- 229920000867 polyelectrolyte Polymers 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 229920002873 Polyethylenimine Polymers 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 229960000633 dextran sulfate Drugs 0.000 claims description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-L glycerol 2-phosphate(2-) Chemical compound OCC(CO)OP([O-])([O-])=O DHCLVCXQIBBOPH-UHFFFAOYSA-L 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 3
- 230000010261 cell growth Effects 0.000 abstract description 4
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 5
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexamethylene diamine Natural products NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000002262 Schiff base Substances 0.000 description 4
- 150000004753 Schiff bases Chemical class 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000006552 photochemical reaction Methods 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Chemical group O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Definitions
- the invention relates to a reactive two -component hydrogel for multifunctional wound dressings with a sensitive effect for promoting the healing result, in particular of chronic wounds with an alkaline pH.
- the invention further relates to a process of the preparation of this reactive two-component hydrogel.
- the skin is the first defensive line of the human body.
- When the skin is damaged leakage from the microvessels causes an increase in the pH of the wound surface to physiological pH (7.4), which gradually increases with increasing wound depth due to the presence of ammonia released from the urea.
- the alkaline pH of chronic wounds in the range of 7.15 to 8.9 causes slow healing due to the stimulation of numerous proteases that cleave proteins, form toxic end products and promote polymicrobial infections, especially anoxic bacteria.
- the target product should have several attributes, namely: (1) should be easy to apply and remove, (2) provide protection against pathogens, (3) maintain a microenvironment for optimal epithelial cell growth, (4) provide wound hydration and stimulate its healing, (5) remove problems related to wound healing, such as creating of scars.
- the chitosan hydrogel dressing is prepared from 1 to 8 parts of chitosan or a derivative thereof, from 0.1 to 3 parts of g-polyglutamic acid or a salt thereof and 6 to 10 parts of oxidized hyaluronic acid or a salt thereof.
- the chitosan hydrogel dressing based on the above invention can be prepared by oxidizing water as a solvent and biological crosslinking agent by the hyaluronic acid based by the Schiff base reaction when no additional crosslinking agents and initiators need to be added. The costs and biological toxicity of the gel are dramatically reduced and the safety of the clinical use of the gel material is ensured.
- the chitosan dressing has excellent biocompatibility and water absorption, is safe, does not contain toxins and neither the production process nor the degraded dressing pollute the environment.
- PCT International Patent Application No. W02014161085 deals with a wound dressing comprising a flexible pharmaceutically acceptable carrier material and a hydrogel applied thereon.
- the hydrogel contains an aldehyde hyaluronic acid prepared by modifying hyaluronic acid with l-amino-3, 3-diethoxypropane and chitosan conjugated to this aldehyde hyaluronic acid through the Schiff base reaction.
- the supporting material may be a fabric with natural and/or synthetic fibres, optionally the support material may be a polymeric film.
- the wound dressing may further comprise one or more components of a buffer, emollient and antimicrobial composition.
- the subject of the Chinese patent No. CN106243410 is a dual- network hydrogel composed of hydroxyethyl chitosan and hyaluronic acid and a process of its preparation. Its preparation comprises the following steps: separate modification of hydroxyethyl chitosan and hyaluronic acid with glycidyl methacrylate to obtain hydroxyethyl chito san-grafted glycidyl methacrylate and hyaluronic acid-grafted glycidyl methacrylate.
- Glycidyl methacrylate grafted with hydroxyethyl chitosan is photochemically polymerized to obtain a hydroxyethyl chitosan hydrogel of the first network, and the hydroxyethyl chitosan hydrogel is lyophilized, impregnated in an aqueous photoinitiator solution and glycidyl methacrylate grafted with hyaluronic acid and photochemically polymerized; thereby obtaining a hydroxyethyl chitosan hydrogel of the second network.
- the hydrogel has adjustable mechanical and swelling properties, high molding speed, simple process and good structural stability. It can be used to construct a 3D model of an in vitro tumour, drug delivery, tissue regeneration, etc.
- hydrogels are prepared on the basis of mixtures (blends) which contain two or more polymers. Chemical reactions are used in the preparation of polymer blends, e.g. using Schiff base or photochemical reactions.
- the invention of a reactive two-component hydrogel for multifunctional wound dressings with a sensitive effect to promote the healing result, in particular of chronic wounds with an alkaline pH, contributes to a large extent to overcoming the above-mentioned drawbacks of the known solutions listed above.
- the reactive two-component hydrogel results from an in situ reaction of two oppositely charged hydrogel components, the first component being a chitosan-based hydrogel, which forms a drug delivery system for protection against invading pathogens, and the second component is a hyaluronic acid-based hydrogel forming a supporting structure for mesenchymal stem cells to create a micro-environment for optimal growth of regenerating cells.
- the first component being a chitosan-based hydrogel, which forms a drug delivery system for protection against invading pathogens
- the second component is a hyaluronic acid-based hydrogel forming a supporting structure for mesenchymal stem cells to create a micro-environment for optimal growth of regenerating cells.
- the first component - a chitosan-based hydrogel is a suitable positively charged heat- sensitive hydrogel resulting from the gelation of chitosan in the presence of B-glycerol phosphate.
- This hydrogel is a matrix for polyelectrolyte nanoparticles based on chitosan, with chitosan being further modified with a hydrophobic amino acid with an aliphatic hydrocarbon side chain, in particular alanine, and forming a system for dosing the antibiotic rifampin, resp. rifampicin.
- rifampicin is trapped in the core of polyelectrolyte nanoparticles, which contain an amphiphilic chitosan core and an alkaline pH coating based on ionically cross- linked dextran sulfate and polyethyleneimine.
- the second component - a hyaluronic acid hydrogel is a suitable negatively charged hydrogel that results from the gelation of hyaluronic acid in the presence of guanine and L- ascorbic acid and forms a support structure for mesenchymal stem cells to create a microenvironment for optimal growth of regenerating cells.
- the process of preparing the reactive two-component hydrogel according to this invention lies in filling each of the hydrogel components into one of separate containers.
- One reservoir is filled with a chitosan-based hydrogel, which forms a drug delivery system to protect against invading pathogens, and the other is a hyaluronic acid-based hydrogel forming a supporting structure for mesenchymal stem cells to prepare a microenvironment for optimal regenerating cell growth.
- a sol-gel transition occurs first due to an increase in ambient temperature and then to their interaction due to electrostatic interactions between these oppositely charged hydrogel components and the alkaline pH of the chronic wound.
- each of the hydrogel components into one of the separate chambers of the two-chamber package, e.g. hyaluronic forming a support structure for mesenchymal stem cells to prepare a microenvironment for optimal growth of regenerating cells.
- these components are simultaneously expelled from both chambers, they then come into contact in a common container and subsequently interact with each other due to a change in ambient temperature, the opposite charge of both hydrogel components and the alkaline pH of the chronic wound.
- Chitosan and hyaluronic acid are among the most important biomacromolecules in forming hydrogels, which are able to retain large amounts of water thanks to their hydrophilic structure.
- Chitosan composed of glucosamine and N-acetylglucosamine is widely used in tissue engineering, wound healing and other biomedical applications because its properties include high biocompatibility, biodegradability, low immunogenicity, antibacterial effects and mucoadhesiveness.
- the chito san-based hydrogel also has great potential for the use in the area of intelligent hydrogels that respond to changes in pH and surrounding temperature.
- Chitosan is soluble in an acidic environment with a pH below 6.2 to 6.5 and at higher pH values forms a hydrated gel-like precipitate due to deprotonation of amines and the formation of hydrogen bonds.
- Heat- sensitive hydrogels can also be formed from high-deacetylated chitosan in the presence of certain phosphates, by grafting or by simple mixing with other polymers.
- Rifampin is a hydrophobic semi- synthetic antibiotic with a broad spectrum of activity against most gram-positive and some gram- negative bacteria, especially microorganisms adhering to the surface in the form of bio films.
- the use of rifampin is limited by various complications, such as low bio availability, poor solubility, short biological half-life, modification of the skin microbiome, resistance to this antibiotic and its high hepatotoxicity.
- polyelectrolyte nanoparticles are used to encapsulate rifampin in order to increase its bio availability by reducing the interaction with the alkaline wound microenvironment.
- the polyelectrolyte nanoparticles contain an amphiphilic chitosan core for capturing hydrophobic rifampin and a alkaline pH coating based on ionically cross-linked dextran sulphate and polyethyleneimine.
- chitosan is modified with a hydrophobic amino acid with an aliphatic hydrocarbon side chain, especially alanine.
- Hyaluronic acid a linear glycosaminoglycan composed of repeating units of N-acetyl- D glucosamine and D-glucuronic acid, shows excellent potential in cell therapeutic therapy. Due to its key physicochemical properties, including biocompatibility, biodegradability, oxygen and nutrient permeability, and tuneable physical and mechanical properties, hyaluronic acid has the potential to control cell migration, growth, and organization. The rapid degradation of hyaluronic acid, which reduces its effectiveness in tissue engineering can be solved by simply modifying the functional groups.
- the hyaluronic acid hydrogel is suitably modified with guanine due to its hydrophobic structure and its important functions in accelerating wound healing.
- L-ascorbic acid is used to create functional double filler materials that can be bioactive and contribute to the regeneration and viability of mesenchymal stem cells and to the formation of hydrogels.
- L- ascorbic acid has various functions in wound healing, and its deficiency results in impaired healing and immune response, decreased collagen synthesis, fibroblast proliferation, angiogenesis, increased capillary fragility, and susceptibility to wound infection.
- L-ascorbic acid with a pKa of 4.17 also accelerates gel formation in the two-component hydrogel by electrostatic interactions when applied topically.
- the resulting two-component stimulus-responsive hydrogel is formed in situ by reacting of two oppositely charged chito san-based and hyaluronic acid-based hydrogel components sequentially in three steps. Gel formation is induced above its gelation temperature (i.e. above room temperature) after two oppositely charged hydrogels combine to form an alkaline chronic wound.
- the chito san-based hydrogel will serve to deliver rifampin-charged polyelectrolyte nanoparticles, the hyaluronic acid hydrogel prepared in the presence of guanine and L-ascorbic acid has a positive effect on mesenchymal stem cell regeneration.
- the basic difference between the above-mentioned known solutions and the reactive two-component hydrogel for multifunctional wound dressing according to this invention is that while in the known solutions hydrogel based mixtures of two or more polymers are being prepared, according to this invention two separately prepared and stored hydrogels consisting of different polymers come into contact only during the process of application. While the known solutions use chemical reactions (e.g. with Schiff base or photochemical reactions) in the preparation of polymer mixtures, the solution according to the invention uses the electrostatic interaction of two hydrogels which act during application. In contrast to the hydrogels from the known solutions, the reactive two-component hydrogel for multifunctional wound dressing according to this invention reacts and is sensitive to external stimuli.
- the sol-gel transition of the reactive hydrogel according to this invention takes place in three steps: above its gelation temperature, after contact of two oppositely charged hydrogels and after getting in contact with the basic environment of the chronic wound.
- the advantage is that the two hydrogel components of the reactive hydrogel are filled in two separate chambers of the package, which eliminates the problems of chemical and physical stability due to the interaction of both components and guarantees a long shelf life.
- a graft copolymer of alanine and chitosan (A-g-CS) is prepared by grafting alanine onto chitosan using EDC / NHS (1 -ethyl-3- (3-dimethylaminopropyl) carbodiimide / N- hydroxysuccinimide) crosslinking agents in stoichiometric amounts.
- EDC / NHS (1 -ethyl-3- (3-dimethylaminopropyl) carbodiimide / N- hydroxysuccinimide) crosslinking agents in stoichiometric amounts.
- the lyophilized products are then stored at -20 ° C.
- G-HMDA guanine- 1,6-hexamethylenediamine
- MeCN metal cyanide
- N-bromosuccinimide is added while constant stirring and the mixture is then filtered.
- the residual solid substance is transferred in acetone while stirring, then is stored at -20 ° C for 48 hours and filtered again.
- the orange solid substance is then washed with cold acetone and dries through which 8-bromoguanosine (G-Br) is achieved. It is then dissolved in a solution of 1,6-hexamethylenediamine (HMDA).
- the pH of the resulting solution is adjusted to 9.8 with concentrated HC1, and the solution is heated up and maintained at 115 ° C at constant stirring. After cooling to room temperature, it is precipitated in distilled water and filtered.
- the next step is the synthesis of HA-HMDA-G (hyaluronic acid- 1,6- hexamethylenediaminoguanine).
- EDC / NHS crosslinking agents l-ethyl-3- (3-dimethylaminopropyl) carbodiimide / N- hydroxysuccinimide
- G-HMDA is added at pH 4.7 while stirring for 24 hours at laboratory temperature .
- the reaction mixture is dialyzed (MWCO 12 kDa) against dilute hydrochloric acid (pH 3-5) and then against distilled water (dH2018).
- L-ascorbic acid is then added to the hydrogel at 4 ° C in an optimized molar ratio and the mixture is stirred overnight.
- MSCs mesenchymal stem cells growth in the hydrogel follows.
- MSCs are cultured in a-modified minimal essential medium (a-MEM) with 10% fetal bovine serum (FBS) and 1% antibiotics.
- a-MEM minimal essential medium
- FBS fetal bovine serum
- 1% antibiotics 1% antibiotics.
- Each of the prepared hydrogel components is filled into one of the separate chambers of a two-chamber package - namely a two-chamber squeezing tube - so that one of the chambers contains a chito san-based hydrogel, which forms a drug delivery system to protect against invading pathogens and the other one contains hyaluronic acid based hydrogel forming a support structure for mesenchymal stem cells to prepare a microenvironment for optimal growth of regenerating cells.
- these components When these components are simultaneously expelled from both chambers, they come into contact in a common outlet of the package and subsequently interact with each other due to the changed ambient temperature, the opposite charge of both hydrogel components and the alkaline pH of the chronic wound. Gel formation is induced above its gelation temperature (i.e. above room temperature) after two oppositely charged hydrogels come into contact and affect the alkaline environment of the chronic wound.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2020409A CZ2020409A3 (cs) | 2020-07-13 | 2020-07-13 | Reaktivní dvousložkový hydrogel pro multifunkční krytí ran a způsob jeho přípravy |
PCT/CZ2021/050074 WO2022012703A1 (en) | 2020-07-13 | 2021-07-09 | A reaction two-component hydrogel for multifunctional wound dressing and method of its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4178538A1 true EP4178538A1 (de) | 2023-05-17 |
Family
ID=77563862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21763000.3A Pending EP4178538A1 (de) | 2020-07-13 | 2021-07-09 | Zweikomponenten-reaktionshydrogel für multifunktionswundverband und verfahren zu seiner herstellung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4178538A1 (de) |
CZ (1) | CZ2020409A3 (de) |
WO (1) | WO2022012703A1 (de) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150283287A1 (en) * | 2012-11-06 | 2015-10-08 | Imbed Biosciences, Inc. | Methods and compositions for wound healing |
WO2014161085A1 (en) * | 2013-04-02 | 2014-10-09 | University Of Manitoba | Schiff-based aldehydic hyaluronic acid-chitosan hydrogel compositions and uses thereof |
-
2020
- 2020-07-13 CZ CZ2020409A patent/CZ2020409A3/cs unknown
-
2021
- 2021-07-09 EP EP21763000.3A patent/EP4178538A1/de active Pending
- 2021-07-09 WO PCT/CZ2021/050074 patent/WO2022012703A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022012703A1 (en) | 2022-01-20 |
CZ2020409A3 (cs) | 2022-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peers et al. | Chitosan hydrogels for sustained drug delivery | |
Seidi et al. | Chitosan-based blends for biomedical applications | |
Yazdi et al. | Agarose-based biomaterials for advanced drug delivery | |
Sun et al. | Recent advances of injectable hydrogels for drug delivery and tissue engineering applications | |
Thambi et al. | Stimuli‐sensitive injectable hydrogels based on polysaccharides and their biomedical applications | |
Coviello et al. | Polysaccharide hydrogels for modified release formulations | |
Wu et al. | Chitosan-based composite hydrogels for biomedical applications | |
Bhattarai et al. | Chitosan-based hydrogels for controlled, localized drug delivery | |
Kim et al. | Natural and synthetic biomaterials for controlled drug delivery | |
EP3412313B1 (de) | Temperaturempfindliche hydrogelzusammensetzung mit nukleinsäure und chitosan | |
Berger et al. | Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications | |
Aminabhavi et al. | Production of chitosan-based hydrogels for biomedical applications | |
Luanda et al. | Past, present and future of biomedical applications of dextran-based hydrogels: A review | |
Vasiliu et al. | Chitosan-based polyelectrolyte complex hydrogels for biomedical applications | |
Pelegrino et al. | Chitosan-Based Nanomaterials for Skin Regeneration. | |
Qureshi et al. | Polysaccharide-based polymeric gels as drug delivery vehicles | |
KR20120118559A (ko) | 생체적합성 히알루론산 가교물을 포함하는 약물 전달 조성물 | |
Ai et al. | Nanocellulose-based hydrogels for drug delivery | |
Neamtu et al. | Nanogels containing polysaccharides for bioapplications | |
Almajidi et al. | Advances in chitosan-based hydrogels for pharmaceutical and biomedical applications: A comprehensive review | |
Feng et al. | Natural Hydrogels Applied in Photodynamic Therapy | |
WO2022012703A1 (en) | A reaction two-component hydrogel for multifunctional wound dressing and method of its preparation | |
Dey et al. | Chitosan nanocomposites for biomedical applications | |
Li et al. | Insight Into Bioactive Hydrogels for Wound Healing and Drug Delivery Systems | |
Moscovici et al. | Bacterial polysaccharides versatile medical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230203 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |